生物标志物评估老年慢性肾脏病患者心功能的研究进展

doi:10.3969/j.issn.1004-583X.2022.09.018

摘要/Abstract

摘要：

全球约有十分之一的人患有慢性肾脏病(chronic kidney disease, CKD),并且在老年人群中,CKD和心血管疾病常同时发生。生物标志物有助于识别其中的高危患者,对于疾病的早期发现和诊疗至关重要。本文通过对生物标志物在老年CKD中的研究进展进行综述,旨在尽早发现老年CKD患者并发心血管疾病时心功能的变化特点。

关键词: 肾脏病学, 心脏功能试验, 老年人, 生物标志物

中图分类号:

R692

马洪珍, 张涛. 生物标志物评估老年慢性肾脏病患者心功能的研究进展[J]. 临床荟萃, 2022, 37(9): 855-859.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.09.018

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I9/855

参考文献 42

[1]	Roux-Marson C, Baranski JB, Fafin C, et al. Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease[J]. BMC Geriatr, 2020, 20(1): 87. doi: 10.1186/s12877-020-1485-4 pmid: 32131742
[2]	Sun L, Tan X, Cao X, et al. Assessed value of high-sensitivity cardiac troponin T for cardiovascular disease among CKD patients[J]. Ren Fail, 2016, 38(5): 728-737. doi: 10.3109/0886022X.2016.1158040 pmid: 26984066
[3]	Wettersten N, Maisel AS. Biomarker developments in heart failure: 2016 and beyond[J]. Curr Opin Cardiol, 2019, 34(2): 218-224. doi: 10.1097/HCO.0000000000000596 pmid: 30633074
[4]	Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review[J]. JAMA, 2019, 322(13): 1294-1304. doi: 10.1001/jama.2019.14745 pmid: 31573641
[5]	Murton M, Goff-Leggett D, Bobrowska A, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: A systematic review[J]. Adv Ther, 2021, 38(1): 180-200. doi: 10.1007/s12325-020-01568-8 pmid: 33231861
[6]	Tuegel C, Bansal N. Heart failure in patients with kidney disease[J]. Heart, 2017, 103(23): 1848-1853. doi: 10.1136/heartjnl-2016-310794 pmid: 28716974
[7]	Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: Epidemiology, mechanisms and management[J]. Nat Rev Nephrol, 2016, 12(10): 610-623. doi: 10.1038/nrneph.2016.113 pmid: 27573728
[8]	Wang K, Zelnick LR, Anderson A, et al. Cardiac biomarkers and risk of mortality in CKD (the CRIC Study)[J]. Kidney Int Rep, 2020, 5(11): 2002-2012. doi: 10.1016/j.ekir.2020.08.028 pmid: 33163721
[9]	宋昊岚, 杨婷婷, 李贵星. N末端脑利钠肽前体(NT-proBNP)在评估慢性肾脏疾病患者心功能中的价值[J]. 四川大学学报(医学版), 2017, 48(4): 561-565.
[10]	李俐, 肖俊会, 毕健成, 等. 老年慢性心力衰竭患者血浆BNP、TNF-α和血清cTnI水平与心室重构指标及心功能的相关性[J]. 中国老年学杂志, 2019, 39(5): 1031-1034.
[11]	Bansal N, Zelnick LR, Soliman EZ, et al. Change in cardiac biomarkers and risk of incident heart failure and atrial fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) study[J]. Am J Kidney Dis, 2021, 77(6): 907-919. doi: 10.1053/j.ajkd.2020.09.021 URL
[12]	Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship[J]. Eur J Clin Invest, 2014, 44(3): 303-308. doi: 10.1111/eci.12234 pmid: 24372567
[13]	Jafri L, Kashif W, Tai J, et al. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: Selecting the optimal heart failure marker in patients with impaired kidney function[J]. BMC Nephrol, 2013, 14: 117. doi: 10.1186/1471-2369-14-117 pmid: 23725445
[14]	Mueller C, Mcdonald K, De Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations[J]. Eur J Heart Fail, 2019, 21(6): 715-731. doi: 10.1002/ejhf.1494 pmid: 31222929
[15]	Januzzi J, Chen-Tournoux A, Christenson R, et al. N-terminal pro-B-type natriuretic peptide in the emergency department: The ICON-RELOADED study[J]. J Am Coll Cardiol, 2018, 71(11): 1191-1200. doi: S0735-1097(18)30166-9 pmid: 29544601
[16]	Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure[J]. Biochim Biophys Acta, 2013, 1832(12): 2442-2450. doi: 10.1016/j.bbadis.2012.12.014 pmid: 23313577
[17]	Plawecki M, Morena M, Kuster N, et al. sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling: Impact on risk prediction[J]. Mediators Inflamm, 2018, 2018: 3952526.
[18]	汤丰宁, 龙勇, 丁宁, 等. sST2、IL-33与慢性肾衰竭患者心力衰竭的相关性研究[J]. 中国医学前沿杂志(电子版), 2019, 11(4): 44-48.
[19]	Mirna M, Topf A, Wernly B, et al. Novel biomarkers in patients with chronic kidney disease: An analysis of patients enrolled in the GCKD-study[J]. J Clin Med, 2020, 9(3):886. doi: 10.3390/jcm9030886 URL
[20]	Benes J, Kotrc M, Wohlfahrt P, et al. The role of GDF-15 in heart failure patients with chronic kidney disease[J]. Can J Cardiol, 2019, 35(4): 462-470. doi: S0828-282X(18)31389-8 pmid: 30935637
[21]	Stein NR, Zelnick LR, Anderson AH, et al. Associations between cardiac biomarkers and cardiac structure and function in CKD[J]. Kidney Int Rep, 2020, 5(7): 1052-1060. doi: 10.1016/j.ekir.2020.04.031 pmid: 32647762
[22]	Tummalapalli SL, Zelnick LR, Andersen AH, et al. Association of cardiac biomarkers with the Kansas City Cardiomyopathy Questionnaire in patients with chronic kidney disease without heart failure[J]. J Am Heart Assoc, 2020, 9(13): e014385. doi: 10.1161/JAHA.119.014385 URL
[23]	Bayes-Genis A, Zamora E, De Antonio M, et al. Soluble ST2 serum concentration and renal function in heart failure[J]. J Card Fail, 2013, 19(11): 768-775. doi: 10.1016/j.cardfail.2013.09.005 pmid: 24263122
[24]	Desmedt V, Desmedt S, Delanghe JR, et al. Galectin-3 in renal pathology: More than just an innocent bystander[J]. Am J Nephrol, 2016, 43(5): 305-317. doi: 10.1159/000446376 pmid: 27166158
[25]	班爱军, 赵云程, 郝耀辉, 等. 慢性肾脏病患者循环半乳糖凝集素3和N端前脑钠肽水平与心力衰竭的关系[J]. 微循环学杂志, 2017, 27(4): 51-55.
[26]	Myhre PL, Claggett B, Ballantyne CM, et al. Association between circulating troponin concentrations, left ventricular systolic and diastolic functions, and incident heart failure in older adults[J]. JAMA Cardiol, 2019, 4(10): 997-1006. doi: 10.1001/jamacardio.2019.3113 pmid: 31483438
[27]	Mishra RK, Li Y, Ricardo AC, et al. Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC])[J]. Am J Cardiol, 2013, 111(3): 432-438. doi: 10.1016/j.amjcard.2012.10.019 pmid: 23178053
[28]	Colbert G, Jain N, de Lemos JA, et al. Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD[J]. Clin J Am Soc Nephrol, 2015, 10(3): 515-529. doi: 10.2215/CJN.03600414 URL
[29]	Chotivanawan T, Krittayaphong R. Normal range of serum highly-sensitive troponin-T in patients with chronic kidney disease stage 3-5[J]. J Med Assoc Thai, 2012, 95(Suppl 2) :S127-S132.
[30]	Hasegawa M, Ishii J, Kitagawa F, et al. Plasma neutrophil gelatinase-associated lipocalin as a predictor of cardiovascular events in patients with chronic kidney disease[J]. Biomed Res Int, 2016, 2016: 8761475.
[31]	Park M, Hsu CY, Go AS, et al. Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death: The CRIC study[J]. Clin J Am Soc Nephrol, 2017, 12(5): 761-771. doi: 10.2215/CJN.08560816 URL
[32]	Huerta A, López B, Ravassa S, et al. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: Potential role of altered collagen metabolism[J]. J Hypertens, 2016, 34(1): 130-138. doi: 10.1097/HJH.0000000000000757 pmid: 26575701
[33]	宋培. 3种血清标志物在尿毒症合并心力衰竭诊断中的应用价值[J]. 国际检验医学杂志, 2019, 40(20): 2475-2478.
[34]	Tedeschi A, Agostoni P, Pezzuto B, et al. Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid[J]. Eur J Prev Cardiol, 2020, 27(2_suppl): 35-45. doi: 10.1177/2047487320957793 pmid: 33238740
[35]	Kube J, Ebner N, Jankowska E A, et al. The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure[J]. Int J Cardiol, 2016, 219: 84-91. doi: 10.1016/j.ijcard.2016.05.006 pmid: 27288971
[36]	Li J, Cui Y, Huang A, et al. Additional diagnostic value of growth differentiation factor-15 (GDF-15) to N-terminal B-type natriuretic peptide (NT-proBNP) in patients with different stages of heart failure[J]. Med Sci Monit, 2018, 24: 4992-4999. doi: 10.12659/MSM.910671 URL
[37]	Gergei I, Krämer BK, Scharnagl H, et al. Renal function, N-terminal pro-B-type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction[J]. Peptides, 2019, 111: 112-117. doi: S0196-9781(18)30071-8 pmid: 29684593
[38]	蒋桂珍, 章丽娟, 周雪芬. NT-proBNP联合红细胞分布宽度预测老年慢性心力衰竭合并Ⅱ型心肾综合征的临床价值[J]. 心脑血管病防治, 2020, 20(4): 375-379.
[39]	Plawecki M, Morena M, Kuster N, et al. sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling: Impact on risk prediction[J]. Mediators Inflamm, 2018, 2018: 3952526.
[40]	胡俊恒, 黄志敏, 冯玉婵. 血清CK-MB、BNP、Scr联合检测对尿毒症患者心衰的诊断价值探究[J]. 中国医学创新, 2020, 17(16): 115-118.
[41]	王精文, 张欢, 赵冠杰, 等. NT-pro BNP联合Cys-C评估慢性肾脏病患者心功能的价值[J]. 中国实验诊断学, 2020, 24(10): 1598-1601.
[42]	吴锡信, 洪明, 胡蓉. N末端B型脑钠肽前体与血清肌酐、胱抑素C比值对慢性肾脏病并心力衰竭的诊断价值[J]. 国际医药卫生导报, 2015, 21(14): 1989-1991, 2004.

生物标志物评估老年慢性肾脏病患者心功能的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王红, 金润浩. 社区老年人自我忽视的研究进展[J]. 临床荟萃, 2024, 39(2): 164-167.
[2]	刘铎, 李燕玲, 郭朝霞, 李建锋, 张惠娟, 谢萍. 左冠状动脉异常起源于主肺动脉综合征1例并文献复习[J]. 临床荟萃, 2023, 38(7): 618-622.
[3]	王友芳, 李兴超, 朱晓松, 周廷发, 张建国, 杨淑红, 相然, 张蒙蒙, 车峰远. 肾功能亢进对重症监护室老年患者注射用头孢哌酮舒巴坦钠应用疗效的预测价值[J]. 临床荟萃, 2023, 38(4): 335-339.
[4]	柴春艳, 王婷. 老年高钙血症3例并文献复习[J]. 临床荟萃, 2023, 38(2): 166-169.
[5]	陈璨, 黄永芬, 苗雨青. 老年急性髓样白血病的治疗进展[J]. 临床荟萃, 2023, 38(10): 954-960.
[6]	曹晶晶, 张英杰, 常丽娟. 心房颤动发病机制及相关生物标志物研究进展[J]. 临床荟萃, 2022, 37(10): 946-949.
[7]	李靖, 王保兴. 慢性肾脏病患者血管钙化的研究进展[J]. 临床荟萃, 2021, 36(9): 850-855.
[8]	张圆, 黄涛, 王保平. 血乳酸辅助APACHEⅡ判断ICU老年重症感染患者预后的临床意义[J]. 临床荟萃, 2021, 36(7): 604-607.
[9]	张金金, 靳蕊霞, 孙伟. 高通量血液透析对老年终末期肾脏病患者衰弱的影响[J]. 临床荟萃, 2021, 36(4): 328-331.
[10]	陈易欣, 周芳芳, 罗群. 急性肾损伤集束化治疗的研究进展[J]. 临床荟萃, 2021, 36(4): 370-373.
[11]	刘巧雪, 魏辉. 急性髓细胞白血病的规范化治疗[J]. 临床荟萃, 2021, 36(10): 880-883.
[12]	张新卉, 谷雨萌, 王仲言, 王东来, 夏晓爽, 王林, 刘霞. 三甲医院和社区医院老年慢性病共病现状调查[J]. 临床荟萃, 2021, 36(1): 39-43.
[13]	郝珍1，李巍2a，于洪伟2b，江珊2b. 沙库巴曲缬沙坦钠对左心室射血分数保留心力衰竭患者的近期疗效[J]. 临床荟萃, 2020, 35(6): 503-507.
[14]	吕雅蕾1，宋丽娜2，单玉洁1，张晓琳3a，贾金海3b. 恩度联合顺铂对老年肿瘤患者恶性腹水的疗效[J]. 临床荟萃, 2020, 35(2): 162-165.
[15]	罗迪, 王小飞, 王蕾. 冠心病患者中心动脉血压与肱动脉血压的差值及影响因素[J]. 临床荟萃, 2020, 35(12): 1089-1092.